Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Supernus Pharmaceuticals Inc Stock Research

SUPN

27.53USD-0.13(-0.47%)Market Closedas of 21 Sep 2023, 09:55 am
Watchlist

Market Summary

USD27.53-0.13
Market Closedas of 21 Sep 2023, 09:55 am
-0.47%

SUPN Alerts

SUPN Stock Price

SUPN RSI Chart

SUPN Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

34.62

Price/Sales (Trailing)

2.37

EV/EBITDA

13.21

Price/Free Cashflow

21.2

SUPN Price/Sales (Trailing)

SUPN Profitability

EBT Margin

8.23%

Return on Equity

5.71%

Return on Assets

2.9%

Free Cashflow Yield

4.72%

SUPN Fundamentals

SUPN Revenue

Revenue (TTM)

634.0M

Revenue Y/Y

-20.28%

Revenue Q/Q

-11.84%

SUPN Earnings

Earnings (TTM)

43.3M

Earnings Y/Y

-110.57%

Earnings Q/Q

-104.9%

Price Action

52 Week Range

27.4642.09
(Low)(High)

Last 7 days

-7.9%

Last 30 days

-11.9%

Last 90 days

-17.5%

Trailing 12 Months

-19.9%

SUPN Financial Health

Current Ratio

1.21

SUPN Investor Care

Shares Dilution (1Y)

1.55%

Diluted EPS (TTM)

0.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for SUPN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-07
Khattar Jack A.
sold (taxes)
-539,408
32.1
-16,804
president, ceo
2023-09-07
Bhatt Padmanabh P.
acquired
-
-
2,500
sr. vp of ip, cso
2023-09-07
Khattar Jack A.
acquired
-
-
35,000
president, ceo
2023-09-07
Bhatt Padmanabh P.
sold (taxes)
-37,942
32.1
-1,182
sr. vp of ip, cso
2023-08-30
Martin Tami Tillotson
acquired
194,319
23.99
8,100
sr. v.p., regulatory affairs
2023-08-30
Martin Tami Tillotson
sold
-259,200
32.00
-8,100
sr. v.p., regulatory affairs
2023-08-25
Martin Tami Tillotson
sold
-162,215
31.59
-5,135
sr. v.p., regulatory affairs
2023-05-11
DEC TIMOTHY C
acquired
-
-
1,500
senior vice-president & cfo
2023-05-11
Khattar Jack A.
sold (taxes)
-547,232
36.47
-15,005
president, ceo
2023-05-11
Khattar Jack A.
acquired
-
-
31,250
president, ceo

1–10 of 50

Which funds bought or sold SUPN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
-401
1,954
-%
2023-08-24
Alberta Investment Management Corp
unchanged
-
-87,256
425,109
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
new
-
553,104
553,104
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.65
-459,365
1,929,820
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
5.89
-71,000
507,000
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
0.86
-48,777
250,101
-%
2023-08-18
Legato Capital Management LLC
unchanged
-
-137,646
670,609
0.09%
2023-08-16
CASTLEARK MANAGEMENT LLC
sold off
-100
-4,017,180
-
-%
2023-08-16
Nuveen Asset Management, LLC
reduced
-32.48
-6,802,520
8,666,480
-%
2023-08-16
Bridge City Capital, LLC
added
0.06
-386,272
1,888,610
0.89%

1–10 of 42

Latest Funds Activity

Are funds buying SUPN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SUPN
No. of Funds

Schedule 13G FIlings of Supernus Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
armistice capital, llc
8.06%
4,356,000
SC 13G/A
Feb 09, 2023
vanguard group inc
10.71%
5,789,960
SC 13G/A
Jan 23, 2023
blackrock inc.
17.8%
9,604,073
SC 13G/A
Feb 15, 2022
armistice capital, llc
7.8%
4,136,000
SC 13G/A
Jan 27, 2022
blackrock inc.
15.9%
8,451,022
SC 13G/A
Jan 26, 2022
blackrock inc.
15.9%
8,451,022
SC 13G/A
Feb 16, 2021
armistice capital, llc
5.9%
3,120,000
SC 13G/A
Feb 10, 2021
vanguard group inc
10.06%
5,298,078
SC 13G/A
Jan 25, 2021
blackrock inc.
16.9%
8,912,801
SC 13G
Mar 12, 2020
armistice capital, llc
5.5%
2,888,000
SC 13G

Recent SEC filings of Supernus Pharmaceuticals

View All Filings
Date Filed Form Type Document
Sep 07, 2023
4
Insider Trading
Sep 07, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Aug 30, 2023
144
Notice of Insider Sale Intent
Aug 29, 2023
4
Insider Trading
Aug 25, 2023
144
Notice of Insider Sale Intent
Aug 25, 2023
4
Insider Trading
Aug 25, 2023
4
Insider Trading
Aug 21, 2023
3
Insider Trading
Aug 21, 2023
4
Insider Trading

SUPN Fair Value

Loading...

Peers (Alternatives to Supernus Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
512.5B
29.5B
3.56% 89.32%
78.88
17.36
1.53% 14.16%
423.3B
97.8B
-2.65% 0.10%
32.43
4.33
2.29% -28.92%
272.8B
58.3B
-2.13% 26.48%
17.88
4.63
2.00% -81.24%
189.8B
77.9B
-9.16% -24.26%
8.84
2.44
-23.04% -26.74%
150.1B
45.2B
-5.06% -15.06%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.75% 544.26%
-74.04
4.1K
-86.94% 71.24%
4.5B
4.6B
-11.49% -16.32%
-66.69
0.98
6.60% 42.04%
SMALL-CAP
1.9B
627.1M
-7.75% -1.79%
-1.34
3.1
-0.20% -204.67%
1.5B
634.0M
-11.88% -19.94%
34.62
2.37
0.62% -24.59%
832.3M
244.3M
-4.13% 4.68%
4.22
3.41
-39.50% -4.99%
830.8M
109.5M
21.79% -27.57%
-5.79
7.59
-2.66% -32.13%
480.0M
453.3M
110.37% -71.69%
-0.39
1.06
-16.04% 55.90%
479.1M
31.2M
-7.77% -52.62%
-4.55
15.37
407.54% -26.47%
269.4M
54.6M
-13.04% -44.44%
-2.97
4.93
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Supernus Pharmaceuticals News

Best Stocks
Analyst Upgrades Vericels Price Target to 445.
Best Stocks,
79 minutes ago
GlobeNewswire
Zacks Investment Research
Yahoo Finance
Yahoo Finance

Returns for SUPN

Cumulative Returns on SUPN

15.0%


10-Year Cumulative Returns

0.8%


7-Year Cumulative Returns

-10.8%


5-Year Cumulative Returns

7.4%


3-Year Cumulative Returns

Risks for SUPN

What is the probability of a big loss on SUPN?

95.8%


Probability that Supernus Pharmaceuticals stock will be more than 20% underwater in next one year

45.4%


Probability that Supernus Pharmaceuticals stock will be more than 30% underwater in next one year.

38.1%


Probability that Supernus Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SUPN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Supernus Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Financials for Supernus Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-5.2%634668667659630601580564571556520477424402393408409404409381359
Costs and Expenses-0.9%614619621641578527494441424398347306269250244261264265264242235
  S&GA Expenses-3.7%359372377405365334305260242221201179164155153157158159155152152
  R&D Expenses10.7%83.0075.0075.0078.0078.0077.0090.0087.0085.0091.0076.0078.0078.0073.0069.0079.0083.0086.0089.0076.0068.00
EBITDA-100.0%-14214996.00114108108131155172189177164160157169-----
EBITDA Margin-100.0%-0.21*0.22*0.15*0.18*0.18*0.19*0.23*0.27*0.31*0.36*0.37*0.39*0.40*0.40*0.41*-----
Interest Expenses-43.3%1.002.003.00-9.50-5.30-1.643.002.003.003.003.003.003.002.003.0014.0012.0011.001.009.005.00
Earnings Before Taxes-51.7%27.0055.0061.0028.0057.0077.0073.00111135151169170157152147145142133140136123
EBT Margin-100.0%-0.08*0.09*0.04*0.09*0.13*0.13*0.20*0.24*0.27*0.32*0.36*0.37*0.38*0.38*0.36*-----
Net Income-16.7%43.0052.0061.0038.0057.0073.0053.0082.0010011112712911811611310610510311199.0087.00
Net Income Margin-100.0%-0.08*0.09*0.06*0.09*0.12*0.09*0.14*0.18*0.20*0.24*0.27*0.28*0.29*0.29*0.26*-----
Free Cashflow-100.0%-161-13812093.00125108118163135145177114140131-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-27.8%1,2931,7921,7031,6931,6951,6401,6891,5551,5731,5071,5041,5101,4911,1901,1601,1071,0641,025978923853
  Current Assets-52.1%424883734664625569602668639586630552557557473427391420493391285
    Cash Equivalents-57.7%25.0058.0093.0011117311620321522425628920421122618111787.0012319212435.00
  Inventory-0.6%91.0091.0092.0083.0085.0089.0086.0060.0058.0050.0048.0042.0035.0024.0027.0026.0026.0027.0026.0023.0021.00
  Net PPE-2.9%14.0015.0015.00--17.0017.00--38.0038.0017.0018.0018.0017.0010.004.004.004.007.005.00
  Goodwill0%11711711711711511511840.0078.0078.0078.0089.0088.00--------
Liabilities-57.6%373880816840854811873745787753759801825576565550541545525501462
  Current Liabilities-65.5%253732688726736285315235283241245300269168161150144152161138104
    LT Debt, Current----401401----------------
    LT Debt, Non Current-------379--------------
Shareholder's Equity0.9%920912886853841828816810786754745709666613595557523480453422390
  Retained Earnings-0.2%49749848145645444638037735633232629625622120016613810586.0061.0033.00
  Additional Paid-In Capital1.9%424416408401390383434429424416409403399392388384379374370365362
Shares Outstanding0%54.0054.0054.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0052.0052.0052.0052.0052.0052.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-55.7%72.0016211713812095.00127110120166138150182119143132157135129132109
  Share Based Compensation9.0%22.0020.0018.0017.0016.0018.0018.0017.0017.0017.0017.0017.0016.0016.0015.0014.0013.0012.0011.0010.0010.00
Cashflow From Investing81.6%16993.00-216-91.77-15.24-80.45-81.91-108-114-141-34.70-64.61-61.66-19.24-157-143-109-465-413-466-513
Cashflow From Financing-524.6%-38992.00-10.48-150-155-154-1309.007.006.004.002.003.003.004.004.005.0010.00376376378

SUPN Income Statement

2023-06-30
Condensed Consolidated Statements of Earnings (Loss) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues    
Total revenues$ 135,563$ 170,051$ 289,327$ 322,557
Costs and expenses    
Cost of goods sold21,09120,45744,55138,389
Research and development24,37916,38545,59137,224
Selling, general and administrative86,782100,476172,379190,935
Amortization of intangible assets20,10820,64440,07441,288
Contingent consideration expense (gain)790743(857)1,408
Total costs and expenses153,150158,705301,738309,244
Operating earnings (loss)(17,587)11,346(12,411)13,313
Other income (expense)    
Interest expense(910)(1,810)(2,415)(3,752)
Interest and other income, net1,3701,7886,71616,486
Total other income (expense)460(22)4,30112,734
Earnings (loss) before income taxes(17,127)11,324(8,110)26,047
Income tax expense (benefit)(16,296)3,459(24,227)(7,434)
Net earnings (loss)$ (831)$ 7,865$ 16,117$ 33,481
Earnings (loss) per share    
Basic (in dollars per share)$ (0.02)$ 0.15$ 0.30$ 0.63
Diluted (in dollars per share)$ (0.02)$ 0.14$ 0.29$ 0.57
Weighted average shares outstanding    
Basic (in shares)54,502,99353,426,16354,442,46353,378,319
Diluted (in shares)54,502,99361,397,15959,035,15461,401,694
Net product sales    
Revenues    
Total revenues$ 128,336$ 165,459$ 268,911$ 312,923
Royalty revenues    
Revenues    
Total revenues$ 7,227$ 4,592$ 20,416$ 9,634

SUPN Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 24,706$ 93,120
Marketable securities126,950368,214
Accounts receivable, net136,556165,497
Inventories, net90,56091,541
Prepaid expenses and other current assets44,76615,779
Total current assets423,538734,151
Long-term marketable securities37,47893,896
Property and equipment, net14,18615,173
Intangible assets, net662,389702,463
Goodwill117,019117,019
Other assets38,48939,806
Total assets1,293,0991,702,508
Current liabilities  
Accounts payable and accrued liabilities83,04496,342
Accrued product returns and rebates148,826151,665
Convertible notes, net0401,968
Contingent consideration, current portion20,72021,120
Other current liabilities016,863
Total current liabilities252,590687,958
Contingent consideration, long-term33,39033,847
Operating lease liabilities, long-term34,17735,998
Deferred income tax liabilities, net44,30049,809
Other liabilities8,7348,692
Total liabilities373,191816,304
Stockholders’ equity  
Common stock, $0.001 par value; 130,000,000 shares authorized; 54,592,901 and 54,253,796 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively5554
Additional paid-in capital424,266408,115
Accumulated other comprehensive loss, net of tax(1,775)(3,210)
Retained earnings497,362481,245
Total stockholders’ equity919,908886,204
Total liabilities and stockholders’ equity$ 1,293,099$ 1,702,508
Jack A. Khattar
580
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.